Latest news
25-07-2023 - New JDRF Request For Proposals to Develop Hypoimmunogenic Beta/Islet Cell Sources for Cell Therapies in Type 1 Diabetes
Funding of up to $1 million is available to support the advancement of early preclinical stage hypoimmunogenic pluripotent stem cells (PSCs) for beta cell replacement in T1D into late preclinical or pilot clinical testing.
The Juvenile Diabetes Research Foundation (JDRF) has issued a new RFA - 'Translation of Hypoimmunogenic Beta/Islet Cell Sources into Late Preclinical/Clinical Testing for Cell Therapies in T1D' - to support the advancement of early preclinical stage hypoimmunogenic pluripotent stem cells (PSCs) for beta cell replacement in T1D into late preclinical or pilot clinical testing.
[...]